Member Info for Porky9

@Bramley1967
Totally agree on all parts

I totally agree and really think a move to the NASDAQ would be the way forward now:-
* 1 set of regulations / 1 language
* A market that understands diagnostics
* A significantly bigger market and significantly greater reach
* Correctly rated on a PE ratio in line with our peers
* Quarter updates

As it stands we are simply NOT getting any recognition on the aim. Investors here want to chase Rainbows and buy stocks on Hype not substance. If they issue a trade update they get complaints, if they issue an R&D update they get complaints, they cant win frankly yet the business is still delivering great results.

They are making more profits than ASOS yet shareholders are piling into "potential stocks" with higher market caps that haven't delivered a bean on profit yet. Its total madness.

So if this is it, this is how its going to be then a move to the NASDAQ is the only answer because at the current diabolically low MCAP its now a sitting duck for an acquisition - maybe that's what's going on behind the scenes ????? because II are still adding and the SP is drifting.

Why oh Why am i returning to this BB with so much diss-information....

Read the bloody broker notes;
https://novacyt.com/wp-content/uploads/2021/02/SP-Angel-Update-04.02.2021.pdf

The business is on track to deliver currently 271m of sales 173m EBITDA and cash at bank for acquisitions of 278m IN THE CURRENT YEAR - they can't be any bloody clearer!!!!!!

This is without ANY large contract orders, ABY sales from new product lines, ANY revenues from Acquisitions

I can only assume that there is some specific agenda in posters visiting this board without doing ANY research and trying to convince Retail investors the business has no forward direction and its a waste of time. It is the only one delivering real results from proven revenues. Its supplying 130 countries, employing 140 odd staff, boots on the ground and securing orders in the USA, has 550 products out there and is leading the WORLD on whole genome sequencing, vital for vaccines.

The RNS this morning
"An international specialist in clinical diagnostics"
"The Company is also continuing to build on its strategy for delivering a sustainable, long-term diagnostics business"

Do some dam Research - Annoyed because its so basic - can't people read what's in front of them anymore????????

@VanV
Oh FFS we at least got a nod from shares magazine today and hopefully a few more will follow. The talk on Friday about sequencing is very much on topic so hopefully we get something from that but as you say maybe nobody will cover anything....
Let’s keep it real but also remember to remain positive. It’s hard enough on negative days

@Poidster
I know it’s frustrating posting here but retail investors seeing other aim listed companies ramping and SP rises on fresh air and hype alone and this has become the new normal - we need your contribution to keep this board grounded with facts not fiction
We value your input

A big positive is that today’s R&D update will get the press talking about us and start the PR machine up and this is prior to the massive whole genome sequencing debate on Friday
Starting to get interesting again
Good luck all

@troublesome
Don’t know for sure but suspect one of two reasons:-
1. Commercial, something being added prepared ready to issue alongside the findings report
2. Data once collated is going to be also validated by a Third party such as DHSC or other again to support the commercial application.
As I say there is a purpose for this

If already posted apologies
https://mobile.twitter.com/Kat_Hassard/status/1364511710225252356/photo/1
Maintaining £ 13.65 fair value target
Without further major contracts, partnership deals or revenues from new product launches or revenues from acquisitions due shortly
Looking very good indeed

@JgCW
Still holding strong and still adding as I can afford
We are still materially undervalued and a long long way to go yet
Much more to come
Today’s R& D update was to clear the way for partner deals imo the AZK Saliva test was of specific interest likewise the care home data, there is a purpose for this.
Onwards and upwards from here.

@mikebassets
Yes,indeed we are materially undervalued
Both broker forecasts put us on 170m plus EBITDA this year and that’s without any major contract wins or revenues from these new product ranges
Onwards and upwards from here :)

@Simple
It’s an R&D update, get with it

@Bing007
Great value Share price from here...

I should Coco, at the rate we were going cash at bank within the next year was going to be more than the market cap! SP is a giveaway at this level. Should rebound sharply from here
GLA

And of course that’s where the LFT can come into its own as an Antibody test rather than a Antigen test which is where rest of market are currently.
Wonder what next gen means? Do you think it can accurately deliver an actual antibody percentage level in your system - bloody amazing
Likewise the Saliva test development also could have legs

"Successful implementation of saliva testing"

This is massive but we are left hanging, must be something to follow here? A partnership deal a roll out ? So we have proven results to back a Saliva Test .

Onwards and upwards, yet another string to our bow.

Last year they delivered a trading update at the end of April and released the full audited year results to the year end on May 14th so we will probably follow similar time line this year. The H1 figures to end of June should be known in July.
Sooner we get a rerating the better frankly
GLA

Has been covered here but worth highlighting:-
https://twitter.com/TaylorQuant/status/1364302030177730564

I think we need to take a step back here and remember that we are still not properly rated, we are still on effectively a cash rating. With a half respectable PE Ratio we would not need to be delivering that much bottom line profit to have a share price significantly higher than where we are today. We forget that we are currently delivering more bottom line profits than ASOS. The only way is up from here.

Also remember that all those funds in at £ 9+/ £10+ like Black Rock etc are not in here to make a loss. They will want a return.

GLA

Fully agree Deas999

Funny i was only saying to a colleague earlier, there is a lot of spin out of Whitehall at the moment about how infection rates are falling and how great the vaccines are blah blah but we are all still in lock down!

Once the schools return as you say up it goes. The kids start spreading the virus, not to mention the average parent age is in the 30-40 bracket and they haven't been vaccinated yet. Add to that crappy tests half of the kids wont even bother to do properly and its a nightmare in the making!!!

Good grief another nasty little sucker to add to the list of known variants:-
https://twitter.com/Porky9Here/status/1363249324268933122/photo/2

The rate this is going Top trumps will be issuing a Covid edition. No sorry that was in bad taste, but seriously it is getting bloody ridiculous now and just highlights how important sequencing is. I would say an essential service now.

The SA variant is the one giving us grief in the UK, 235 cases last week and i really wonder what the numbers are today? I suspect they are much higher?. Two more areas went into surge testing mode yesterday on the search for this variant. One in Kent and one was Manchester way i think? Fact is it can escape antibodies which makes it especially dangerous hence why the authorities are so keen to contain.

This new one spreading California sounds equally nasty, very contagious. There were two other variants equally good at evading antibodies found in the Philippines the weekend.

The concern obviously being that if the variants escape antibodies then you could catch covid twice and it will also render vaccines useless or certainly less effective. Fortunately with quality sequencing we at least have a chance to keep mapping and evolving our vaccines to protect the nation.

Right, having waded through all the subtle de-ramping posts on LSE today and end of the world messages, I'm sitting here tonight with a MASSIVE smile on my face; So why is that???

Well elephant out the room first: Yes, I'm as frustrated as everyone else here that the SP has taken yet a further fall on an already undervalued asset, bloody annoying and my paper loss is now even higher however, as i'm not selling anytime in the next twelve months (excepting a forced sale via takeover which is now looking worrying likely) i don't see it as a problem. The SP will catch up with the fundamentals soon and these dark days of uncertainty will clear.

It may amaze some here but i'm still actually confident of my targets. YES, that's right £54 it will still happen....

So why am i so positive?

1 Well first off the business is absolutely booming, demand for its tests are off the scale and every day the cash pile increases. Meanwhile, its going to take a hell of a long time to vaccinate the world and even then high percentages of people either won't bother and we will need to constantly improve and adjust the vaccines just like the flu jab in order to keep on top of variants. Government have confirmed what we already suspected - this is something we are going to have to live with.

2. Novacyt are leading the way, supporting Cog-uk with sequencing and it is looking that not only are Novacyt now ahead of what's going on BUT the UK is leading the world in sequencing. The talk Friday will clarify further. NB. The world needs sequencing data as without it they can't perfect vaccines. We play a vital role.

3. Despite our now worldwide product demand, our products are being used in the NHS AND we are clearly working with partners in this same direction. When Novacyt update us all of this is anyones guess but the focus is on building the business but this update WILL come. Watch this space.

4. The government budget for the COVID testing fund is £ 2bn over the next two years, based on the report out, excepting anything already in the NHS budgets. £ 300m for Sequencing and some of this will go to care home PCR testing so maybe a some coming our way, who knows? Budget for the Surge testing we are active supporting. They have made it clear that Surge testing will continue especially where an new variant is identified.

So in principle: i don't know how much we will get of this £ 2bn allocation, but it will be some; BUT anything we get will be on top of our already stable revenues. The balance will got to LFT providers UK and probably china. where ever is cheapest.

Then we have airports and travel where yet more PCR is confirmed this will be funded via the private sector and im sure some businesses will use versalab or similar BUT again adds .

Now, i could go on but this post is already long enough. Today all stocks in "Covid" got lumped together and bashed. However, ours is built on substance. Its not a hype only stock and we have world wide

Cutting out the white noise the ONLY thing of interest today is the official Government position
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/963491/COVID-19_Response_-_Spring_2021.pdf

And the precise from off the record of same highlighting the bits JUST relevant to our position here:
https://twitter.com/OffRecord2020/status/1364218616519024643

So its £ 2bn of government funding for UK testing over two years - This is the government money on the table.
Split PCR and Non PCR

Great News for NCYT as we have an amazing distribution network of already established worldwide clients. Private sectors clients such as Airports etc will use PCR.

Further investment into sequencing is confirmed (includes us)

Really is onwards and upwards from here... VERY happy

@Soder
In total agreement
I haven't seen anything quite like this in 20 years either, what a strange world we now live in
Ultimately fundamentals will out here